These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 7649071)

  • 21. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychotic symptoms preceding ocular deviation in a patient with tardive oculogyric crises.
    Sachdev P; Tang WM
    Aust N Z J Psychiatry; 1992 Dec; 26(4):666-70. PubMed ID: 1362053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics].
    Caroli F; Littre-Poirier MF; Ginestet D; Deniker P
    Encephale; 1975; 1(1):69-74. PubMed ID: 805695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
    Bransgrove LL; Kelly MW
    Am J Hosp Pharm; 1994 Apr; 51(7):895-9. PubMed ID: 7912473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The treatment of tardive dyskinesia.
    Raja M
    Schweiz Arch Neurol Psychiatr (1985); 1996; 147(1):13-8. PubMed ID: 8685689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
    Reddy S; Factor SA; Molho ES; Feustel PJ
    Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Translation and application of the Simpson and Angus Scale of Extrapyramidal Symptoms].
    Lejoyeux M; Gorwood P; Stalla-Bourdillon A; Adès J
    Encephale; 1993; 19(1):17-21. PubMed ID: 8275889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotic drug side effects: their relationship to dose.
    Kane JM
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):16-21. PubMed ID: 2859276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety.
    Small GW; Bystritsky A
    J Clin Psychiatry; 1997; 58 Suppl 11():24-9. PubMed ID: 9363045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Neuroleptic malignant syndrome. Case reports].
    Berardi D; Troia M; Veronesi L; Ferrari G
    Minerva Psichiatr; 1994 Dec; 35(4):199-219. PubMed ID: 7861943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Modification of schizophrenia by intensive neuroleptic therapy and the course of the disease after withdrawal of neuroleptic drugs].
    Steiner S
    Psychiatr Clin (Basel); 1980; 13(3-4):165-78. PubMed ID: 7244281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of the antiparkinsonian drugs on the plasma level of neuroleptics.
    Gautier J; Jus A; Villeneuve A; Jus K; Pires P; Villeneuve R
    Biol Psychiatry; 1977 Jun; 12(3):389-99. PubMed ID: 871490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Complications of drug withdrawal from antiparkinson agents and neuroleptics].
    Mizon JP; Rosa A
    Therapie; 1984; 39(4):421-5. PubMed ID: 6148792
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs.
    Kabes J; Sikora J; Pisvejc J; Hanzlicek L; Skondia V
    Int Pharmacopsychiatry; 1982; 17(3):185-92. PubMed ID: 6128331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Late extrapyramidal hyperkinesis and neuroleptic withdrawal dyskinesia. Practical problems].
    Hoffmann C; Faust V
    Fortschr Med; 1983 Mar; 101(11):470-6. PubMed ID: 6133824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroleptic malignant syndrome due to depot fluphenazine.
    Grunhaus L; Sancovici S; Rimon R
    J Clin Psychiatry; 1979 Feb; 40(2):99-100. PubMed ID: 762037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment with dimethylaminoethanol (deanol) in neuroleptic induced tardive dyskinesia].
    Kocher R; Hobi V; Linder M; Studer K
    Schweiz Arch Neurol Neurochir Psychiatr; 1980; 126(1):103-9. PubMed ID: 6106283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Follow-up treatment of schizophrenic psychoses: advantages and disadvantages of long-term medication].
    Steuber H; Kind J; Lohrengel S; Müller P
    Arzneimittelforschung; 1978; 28(9):1492-3. PubMed ID: 38806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.